European Commission logo
English English
CORDIS - EU research results

Accelerating drug and biomarker discovery through a new proteomic service: DrugPhosphoProfiler

Periodic Reporting for period 1 - DrugPhosphoProfiler (Accelerating drug and biomarker discovery through a new proteomic service: DrugPhosphoProfiler)

Reporting period: 2019-08-01 to 2019-11-30

At present there is an enormous interest in the pharmaceutical industry to find and develop new drugs targeting protein phosphorylation and their associated biological pathways, given their essential role in almost every pathology. However, the high complexity of these cellular signalling networks and the lack of reliable biological knowledge about them make it very difficult to unveil the mechanism of action of a particular drug as well as its side effects. Moreover, existing technologies fall short from providing comprehensive, robust and quantitative data, which can be turned into information and knowledge about cellular phosphorylation networks, and which is absolutely essential to support faster and more efficient drug discovery and development.
We are developing DrugPhosphoProfiler, an innovative platform combining state-of-the-art mass spectrometry based high throughput analytics and information management technologies for systematically measuring and analysing the effects of pharmaceutical agents on phosphorylation-dependent cellular networks in a proteome-wide and drug concentration-resolved manner. DrugPhosphoProfiler will be a unique, high-content drug discovery and development engine capable of providing essential and quantitative molecular pharmacodynamic data based on 25,000 phosphorylation sites in a single assay. The information and knowledge generated by the DrugPhosphoProfiler platform will increase the success rate of pre-clinical drug discovery as well as clinical trials and ultimately lead to more effective treatments of diseases.
Through this project (estimated ROI of 5.52) we at OmicScouts (SME, Germany) plan to boost the competitiveness of our company and build the basis for future innovations driven by scientific and technological excellence, by increasing our revenues to €54.44 Million and our team to 35 people, just 6 years after commercialization